Follow us for updates
© 2020
Read the Story →

Pfizer COVID-19 Vaccine: What You Need to Know

Details from the Department of Health.
by Arianne Merez
Just now
Photo/s: Shutterstock

The Philippines is targeting to start its mass COVID-19 immunization program by Feb. 15 with the expected arrival of vaccines made by Pfizer and BioNTech.

The vaccine, which has come around with an efficacy of 95%, has been found by the Health Technology Assessment Council to be safe, cost-effective, affordable, and desired by key stakeholders.

The HTAC advises both the Department of Health and state medical insurer PhilHealth.

Here's what you need to know about the Pfizer-BioNTech vaccine according to the HTAC and the Department of Health:

It's for emergency use only.

Health authorities recommend the emergency use of the vaccine for persons aged 16 and older, prioritizing the most at-risk and vulnerable populations.

"The vaccine prevents symptomatic COVID-19 infection in the short term, with benefits outweighing risks," the government's Health Technology Assessment Council said.

"Researchers worldwide continue to collect and monitor data to establish its long-term efficacy, safety, and its potential to reduce COVID-19 transmission," it added.

Continue reading below ↓


Pfizer Vaccine is Approved by DOH Advisory Board

Pfizer Says Its Vaccine Works Against UK, South Africa Variants

Pfizer Vaccine Gets First Ever Emergency Use Authority in Philippines

It's not for everyone.

The following people should not receive the vaccine according to experts:

  • Persons with history of anaphylaxis or allergic reactions (of any severity) to any mRNA COVID-19 vaccine ingredient (such as Polyethylene glycol [PEG] or other related molecules)  that occur within four hours from vaccination
  • Persons with history of anaphylaxis or allergic reactions (of any severity) that occur within four hours after receiving the first dose of the vaccine
  • Persons under 16 years of age

It should be administered in two doses.

Those who are eligible for the Pfizer-BioNTech jab should receive two vaccine doses at least 21 days apart, the DOH said.

Both doses of vaccine should be the Pfizer-BioNTech jab, the DOH said since regulatory bodies have "yet to assess the safety and efficacy of mixed-product dosage series."

Continue reading below ↓

Worried? Consult your doctor first.

The DOH recommends consulting with physicians before taking the vaccine if one has a history of allergic reactions, and illnesses. Here are the guidelines:

  • For those with a history of immediate allergic reaction or hypersensitivity to any other injectable therapy, such as intramuscular, intravenous, or subcutaneous vaccines unrelated to a component of mRNA COVID-19 vaccines, treatment for severe allergic reactions must be made available.
  • For those with concurrent moderate to severe acute illness, for immunocompromised persons, Persons Living with HIV (PLHIV), persons with other autoimmune conditions, and those with a history of Bell’s palsy, vaccination may be subject to physician advice.
  • For pregnant and breastfeeding women excluded from other priority groups, vaccination may be subject to physician advice.

The DOH said there have been reported side-effects of the vaccine for persons with a history of severe hypersensitivity including:

Continue reading below ↓
  • Severe allergic reaction or anaphylaxis
  • Hypersensitivity (such as respiratory distress [wheezing, stridor], urticaria, or angioedema) or allergic reaction of any severity to previous mRNA vaccine dose or its components, occurring 4 hours after administration
  • Allergic reaction of any severity to polysorbate, occurring 4 hours after administration

Pfizer and BioNTech have also reported that their product is effective against coronavirus variants that have emerged in Britain and South Africa.

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.